- Home
- HTD vs LXEO Comparison
HTD vs LXEO Comparison
Compare HTD & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | HTD | LXEO |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 843.6M | 731.3M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | HTD | LXEO |
|---|---|---|
| Price | $25.00 | $6.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $18.60 |
| AVG Volume (30 Days) | 92.3K | ★ 1.0M |
| Earning Date | 01-01-0001 | 03-23-2026 |
| Dividend Yield | ★ 8.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.17 | $1.45 |
| 52 Week High | $22.13 | $10.99 |
Technical Indicators
Market Signals| Indicator | HTD | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 64.54 | 35.45 |
| Support Level | $24.70 | $6.73 |
| Resistance Level | $25.20 | $7.31 |
| Average True Range (ATR) | 0.30 | 0.46 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 87.67 | 14.79 |
Price Performance
Historical ComparisonAbout HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest
John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, convertible bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, communication services, materials, healthcare, real estate, consumer Staples, and short-term investments.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.